ASTRAZENECA: IMFINZI (DURVALUMAB) PLUS TRANSARTERIAL CHEMOEMBOLIZATION (TACE) AND BEVACIZUMAB REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 23% VS. TACE IN LIVER CANCER ELIGIBLE FOR EMBOLIZATION
January 20, 2024
January 20, 2024
WILMINGTON, Delaware, Jan. 20 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Jan. 19, 2024:
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) elig . . .
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) elig . . .